MEDIUM confidence: 100% data completeness, but the composite (50) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $17.4B— | $21.7B+24.3% | $15.6B-28.0% | $16.6B+6.5% | $17.1B+3.1% |
| EPS (dil.) | $-0.07— | $3.88n/m | $3.66-5.7% | $5.74+56.8% | $8.52+48.4% |
| Free Cash Flow | $1.8B— | $1.0B-41.8% | $826M-21.1% | $684M-17.2% | $584M-14.6% |
| Gross Margin | 12.0% | 12.9%+0.9pp | 16.2%+3.3pp | 20.0%+3.8pp | 26.5%+6.5pp |
| Operating Margin | 10.4% | 11.5%+1.0pp | 14.0%+2.5pp | 17.7%+3.7pp | 20.1%+2.4pp |
| Net Margin | 0.4% | 5.3%+4.9pp | 5.3%+0.0pp | 7.6%+2.3pp | 10.8%+3.1pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $309 (last qtr, 14 analysts) → $323 (last mo, 8) (+4.4%).
Buy-rated share 88% → 87% over ~3 months (-1pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $2.83 | $3.54 | +25.1% |
| May 2026 | $2.48 | $2.21 | -10.9% |
| Feb 2026 | $2.30 | $2.51 | +9.1% |
| Nov 2025 | $2.11 | $2.20 | +4.3% |
| Aug 2025 | $1.86 | $2.87 | +54.3% |
| May 2025 | $1.98 | $0.91 | -54.0% |
| Feb 2025 | $1.92 | $1.44 | -25.0% |
| Nov 2024 | $1.56 | $1.75 | +12.2% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 12.2%/yr (revenue basis).
Base free cash flow $698M (avg FY2023–FY2025; latest year $584M) · equity value $57.9B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
Net insider -$28.2M over 180 days (0 open-market buys, 14 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
The QScore of 50 for TRGP indicates a neutral outlook, with the stock's strengths and weaknesses balancing out. The stock scores high on profitability, with a notable ROE of 72.1%, and exhibits strong momentum, having returned 60.5% over the past year. However, it trades at a premium, with a P/E of 25.6 and P/B of 15.9, which weighs on its value score. The long-term and short-term scores are relatively close, with the short-term score slightly higher at 52, suggesting a modest near-term advantage.